What is BCAB's current stock price?

BCAB (BioAtla, Inc.) is currently trading at $3.69 with a market cap of $4.7M.

What sector is BioAtla, Inc. in?

BioAtla, Inc. (BCAB) operates in the Healthcare sector, specifically in the Biotechnology industry.

Is BCAB a good stock to buy?

Analysts have a Buy consensus on BCAB with a price target of $250.00. Check our detailed analysis for valuation, financials, and insider activity.

InvestLog

BCAB BioAtla, Inc.

Healthcare

$3.69+2.07%ClosedMarket Cap: $4.7M

As of 2026-05-25

Valuation

View Details

P/E (TTM)

—

PEG

—

P/B

-0.15

P/S

2.33

EV/EBITDA

-0.18

DCF Value

$-4.98

FCF Yield

-495.6%

Div Yield

0.0%

Margins & Returns

Gross Margin

106.0%

Operating Margin

-2525.0%

Net Margin

-2530.8%

ROE

166.7%

ROA

-590.9%

ROIC

477.9%

Financials

View All

Period	Revenue	Net Income	EPS
Q1 null	$0.00	$-6.3M	$—
Q4 null	$2.0M	$-9.8M	$—
FY null	$2.0M	$-59.6M	$—
Q3 null	$0.00	$-15.8M	$—

Analyst Ratings

View All

Consensus

Buy

Target (Consensus)

$250.00

Target (Median)

$250.00

Target Range

$250.00 - $250.00

0 Strong Buy1 Buy0 Hold0 Sell0 Strong Sell

JMP SecuritiesMarket Perform

2025-08-13

Trading Activity

Insider Trades

View All

Vasquez Christianofficer: Chief Financial Officer

SellThu Mar 12

Sievers Ericofficer: Chief Medical Officer

SellThu Mar 12

SHORT JAY M PHDdirector, officer: Chief Executive Officer

SellThu Mar 12

WALDRON RICHARD Aofficer: Former Chief Financial Officer

SellMon Mar 02

Vasquez Christianofficer: Chief Financial Officer

SellMon Mar 02

Company Info

Sector

Healthcare

Industry

Biotechnology

Country

Exchange

—

Beta

0.79

BioAtla, Inc., a clinical stage biopharmaceutical company, develops specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its lead product candidate is BA3011, a conditionally active biologic (CAB) antibody-drug conjugate (ADC) for soft tissue and bone sarcoma tumors, non-small cell lung cancer (NSCLC), and ovarian cancer. It also develops BA3021, a CAB ADC for multiple solid tumor types, including NSCLC, melanoma, and ovarian cancer; and BA3071, which is a CAB anti-cytotoxic T-lymphocyte-associated antigen 4 antibody for renal cell carcinoma, NSCLC, small cell lung cancer, hepatocellular carcinoma, melanoma, bladder cancer, gastric cancer, and cervical cancer. BioAtla, Inc. was founded in 2007 and is based in San Diego, California.

Peers